Identification

Name
Cabazitaxel
Accession Number
DB06772
Type
Small Molecule
Groups
Approved
Description

Cabazitaxel is an anti-neoplastic used with the steroid medicine prednisone. Cabazitaxel is used to treat people with prostate cancer that has progressed despite treatment with docetaxel. Cabazitaxel is prepared by semi-synthesis with a precursor extracted from yew needles (10-deacetylbaccatin III). It was approved by the U.S. Food and Drug Administration (FDA) on June 17, 2010.

Structure
Thumb
Synonyms
  • Cabazitaxel
  • Cabazitaxelum
  • Taxoid XRP6258
  • TXD258
  • XRP6258
External IDs
RPR-116258A / RPR116258 / TXD 258 / TXD-258 / XRP 6258 / XRP-6258
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
JevtanaSolution40 mgIntravenousSanofi Aventis2011-08-23Not applicableCanada
JevtanaKit60 mg/1.5mLSanofi Aventis2010-06-17Not applicableUs
Categories
UNII
51F690397J
CAS number
183133-96-2
Weight
Average: 835.9324
Monoisotopic: 835.377905537
Chemical Formula
C45H57NO14
InChI Key
BMQGVNUXMIRLCK-OAGWZNDDSA-N
InChI
InChI=1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1
IUPAC Name
(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0³,¹⁰.0⁴,⁷]heptadec-13-en-2-yl benzoate
SMILES
[H][C@@](O)([C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1)C(=O)O[C@@]1([H])C[C@@]2(O)[C@@]([H])(OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@]4([H])C[C@]([H])(OC)[C@@]3(C)C(=O)[C@]([H])(OC)C(=C1C)C2(C)C)OC(C)=O

Pharmacology

Indication

For treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.

Associated Conditions
Pharmacodynamics

Cabaitaxel has anti-tumour properties and is effective against docetaxel-sensitive and -insensitive tumours.

Mechanism of action

Cabazitaxel is a microtubule inhibitor. Cabazitaxel binds to tubulin and promotes its assembly into microtubules while simultaneously inhibiting disassembly. This leads to the stabilization of microtubules, which results in the interference of mitotic and interphase cellular functions. The cell is then unable to progress further into the cell cycle, being stalled at metaphase, thus triggering apoptosis of the cancer cell.

TargetActionsOrganism
ATubulin alpha-4A chain
binder
Human
ATubulin beta-1 chain
binder
Human
Absorption

After an intravenous dose of cabazitaxel 25 mg/m2 every three weeks to a population of 170 patients with solid tumors, the mean Cmax in patients with metastatic prostate cancer was 226 ng/mL (CV 107%) and was reached at the end of the one-hour infusion (Tmax). The mean AUC in patients with metastatic prostate cancer was 991 ng.h/mL (CV 34%). Administration with prednisone or prednisolone do not effect the pharmacokinetic profile of cabazitaxel.

Volume of distribution

The volume of distribution (Vss) was 4,864 L (2,643 L/m2 for a patient with a median BSA of 1.84 m2) at steady state. Compared to other taxanes, penetrates the CNS to a greater extent.

Protein binding

Cabazitaxel is mainly bound to human serum albumin (82%) and lipoproteins (88% for HDL, 70% for LDL, and 56% for VLDL).

Metabolism

Cabazitaxel is extensively metabolized in the liver (>95%), mainly by the CYP3A4/5 isoenzyme (80% to 90%), and to a lesser extent by CYP2C8 which results in 20 different metabolites. Two of these metabolites are active demethylated derivatives of cabaxitaxel and referred to as RPR112698 and RPR123142 respectively. Docetaxel is another metabolite of cabazitaxel. Cabazitaxel is the main circulating moiety in human plasma.

Route of elimination

After a one-hour intravenous infusion [14C]-cabazitaxel 25 mg/m2, approximately 80% of the administered dose was eliminated within 2 weeks. Cabazitaxel is mainly excreted in the feces as numerous metabolites (76% of the dose); while renal excretion of cabazitaxel and metabolites account for 3.7% of the dose (2.3% as unchanged drug in urine).

Half life

Following a one-hour intravenous infusion, plasma concentrations of cabazitaxel can be described by a three-compartment pharmacokinetic model with α-, β-, and γ- half-lives of 4 minutes, 2 hours, and 95 hours, respectively.

Clearance

Cabazitaxel has a plasma clearance of 48.5 L/h (CV 39%; 26.4 L/h/m2 for a patient with a median BSA of 1.84 m2) in patients with metastatic prostate cancer.

Toxicity

Cabazitaxel may cause serious side effects including neutropenia, hypersensitivity reactions, gastrointestinal symptoms, and renal failure. Anticipated complications of overdose include exacerbation of adverse reactions such as bone marrow suppression and gastrointestinal disorders. Cabazitaxel penetrates the blood-brain barrier. LD50, rat = 500 mg/kg

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe metabolism of (R)-warfarin can be decreased when combined with Cabazitaxel.
(S)-WarfarinThe metabolism of (S)-Warfarin can be decreased when combined with Cabazitaxel.
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Cabazitaxel.
3,5-diiodothyropropionic acidThe metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Cabazitaxel.
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be decreased when combined with Cabazitaxel.
5-androstenedioneThe metabolism of Cabazitaxel can be decreased when combined with 5-androstenedione.
6-Deoxyerythronolide BThe metabolism of Cabazitaxel can be decreased when combined with 6-Deoxyerythronolide B.
6-O-benzylguanineThe metabolism of 6-O-benzylguanine can be decreased when combined with Cabazitaxel.
9-(N-methyl-L-isoleucine)-cyclosporin AThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
9-aminocamptothecinThe metabolism of 9-aminocamptothecin can be decreased when combined with Cabazitaxel.
Food Interactions
Not Available

References

Synthesis Reference

Nagesh Palepu, "CABAZITAXEL FORMULATIONS AND METHODS OF PREPARING THEREOF." U.S. Patent US20120065255, issued March 15, 2012.

US20120065255
General References
  1. Galsky MD, Dritselis A, Kirkpatrick P, Oh WK: Cabazitaxel. Nat Rev Drug Discov. 2010 Sep;9(9):677-8. doi: 10.1038/nrd3254. [PubMed:20811375]
  2. Kort A, Hillebrand MJ, Cirkel GA, Voest EE, Schinkel AH, Rosing H, Schellens JH, Beijnen JH: Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Apr 15;925:117-23. doi: 10.1016/j.jchromb.2013.02.034. Epub 2013 Mar 5. [PubMed:23542607]
  3. Nightingale G, Ryu J: Cabazitaxel (jevtana): a novel agent for metastatic castration-resistant prostate cancer. P T. 2012 Aug;37(8):440-8. [PubMed:23091336]
External Links
Human Metabolome Database
HMDB0015672
KEGG Drug
D09755
PubChem Compound
9854073
PubChem Substance
99443289
ChemSpider
8029779
ChEBI
63584
ChEMBL
CHEMBL1201748
PharmGKB
PA165958401
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Cabazitaxel
ATC Codes
L01CD04 — Cabazitaxel
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
FDA label
Download (383 KB)
MSDS
Download (99.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentProstate Cancer1
1Active Not RecruitingTreatmentUrothelial Carcinoma of the Urinary Bladder1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentMetastatic Castration Resistant Prostate Cancer1
1CompletedTreatmentNeoplasms Malignant1
1CompletedTreatmentNeoplasms, Malignant1
1CompletedTreatmentProstate Cancer1
1CompletedTreatmentSolid Cancers1
1CompletedTreatmentTumors, Solid1
1RecruitingTreatmentProstate Cancer1
1WithdrawnTreatmentProstatic Neoplasms1
1, 2Active Not RecruitingTreatmentAdenocarcinoma, Prostate / Castration Levels of Testosterone / Castration-Resistant Prostate Carcinoma / Lymphadenopathy / Metastatic Hormone Refractory Prostate Cancer / Prostate Cancer / Prostate Carcinoma Metastatic in the Bone / Prostate Small Cell Carcinoma1
1, 2CompletedTreatmentMalignant Neoplasm of Stomach1
1, 2CompletedTreatmentMalignant Solid Tumor - Malignant Nervous System Neoplasm1
1, 2RecruitingTreatmentCastration Levels of Testosterone / Castration-Resistant Prostate Carcinoma / Hormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer / Stage IV Prostate Cancer AJCC v71
1, 2TerminatedTreatmentNeoplasms, Malignant1
1, 2TerminatedTreatmentProstate Cancer / Prostatic Neoplasms1
1, 2WithdrawnTreatmentBrain Cancer1
2Active Not RecruitingTreatmentDistal Esophageal Adenocarcinoma / Gastric Adenocarcinoma / Gastroesophageal Adenocarcinoma1
2Active Not RecruitingTreatmentHormone-Resistant Prostate Cancer / Stage IV Prostate Adenocarcinoma1
2Active Not RecruitingTreatmentMetastatic Breast Cancer With Intracranial Metastases1
2Active Not RecruitingTreatmentMetastatic Castration-Resistant Prostatic Cancer1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentGlioblastoma Multiforme (GBM) WHO Grade IV1
2CompletedTreatmentHormone Refractory Prostate Cancer1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2CompletedTreatmentMalignant Neoplasm of Stomach1
2CompletedTreatmentMetastatic Castration Resistant Prostate Cancer1
2CompletedTreatmentMetastatic Head and Neck Cancer / Recurrent Head and Neck Cancer1
2CompletedTreatmentMetastatic Hormone Refractory Prostate Cancer2
2CompletedTreatmentPenile Neoplasms1
2CompletedTreatmentProstatic Neoplasms1
2CompletedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
2CompletedTreatmentTransitional Cell Carcinoma2
2Enrolling by InvitationSupportive CareCastration-Resistant Prostate Cancer (CRPC) / Prostate Cancer1
2Not Yet RecruitingTreatmentCancer treatment / Castration-Resistant Prostate Cancer (CRPC) / Circulating Tumor Cells / Prostate Cancer1
2RecruitingDiagnosticCirculating Tumor Cells / Metastatic Hormone Refractory Prostate Cancer1
2RecruitingTreatmentAdrenocortical Carcinoma1
2RecruitingTreatmentBone Metastatic Prostate Cancer1
2RecruitingTreatmentCancer of the Ovary1
2RecruitingTreatmentCancer of the Prostate / Metastatic Cancers1
2RecruitingTreatmentCastration Levels of Testosterone / Castration-Resistant Prostate Carcinoma / Metastatic Prostate Carcinoma in the Soft Tissue / Prostate Carcinoma Metastatic in the Bone / PSA Progression / Stage IV Prostate Adenocarcinoma AJCC v7 / Stage IV Prostate Cancer AJCC v71
2RecruitingTreatmentHER2 Negative Metastatic Breast Cancer1
2RecruitingTreatmentInfiltrating Bladder Urothelial Carcinoma1
2RecruitingTreatmentLiposarcomas, Dedifferentiated1
2RecruitingTreatmentNon-seminomatous Germ-cell Tumors1
2RecruitingTreatmentProstate Cancer2
2RecruitingTreatmentProstate Cancer / Prostate Cancer Aggressiveness1
2RecruitingTreatmentTesticular Cancer1
2TerminatedSupportive CareHormone-Resistant Prostate Cancer / Recurrent Prostate Cancer / Severe or persistent diarrhea / Stage I Prostate Cancer / Stage IIA Prostate Cancer / Stage IIB Prostate Cancer / Stage III Prostate Cancer / Stage IV Prostate Cancer1
2TerminatedTreatmentCancer of the Ovary1
2TerminatedTreatmentCancer, Breast / Lung Cancers / Progressive Brain Metastases / Recurrent Brain Metastases1
2TerminatedTreatmentColorectal Cancers1
2TerminatedTreatmentEsophageal / Gastrooesophageal Cancer / Malignant Neoplasm of Stomach1
2TerminatedTreatmentProstate Cancer3
2WithdrawnDiagnosticProstatic Neoplasms1
2WithdrawnTreatmentAdvanced Prostate Cancer1
2WithdrawnTreatmentBrain Metastasis / Cancer, Breast / Lung Cancer Non-Small Cell Cancer (NSCLC)1
2WithdrawnTreatmentCastrate-resistant Metastatic Prostate Cancer1
2, 3CompletedTreatmentTransitional Cell Carcinoma1
2, 3RecruitingTreatmentMetastasis / Metastatic Hormone Refractory Prostate Cancer1
2, 3Unknown StatusTreatmentUrothelium Transitional Cell Carcinoma1
3Active Not RecruitingOtherMetastatic Castration Resistant Prostate Cancer1
3CompletedTreatmentMetastatic Hormone Refractory Prostate Cancer1
3CompletedTreatmentNeoplasms / Prostatic Neoplasms1
3CompletedTreatmentProstate Cancer3
3RecruitingTreatmentAdenocarcinoma, Prostate / Progression of Prostate Cancer1
3RecruitingTreatmentMetastatic Hormone Refractory Prostate Cancer1
3TerminatedTreatmentCastrate-resistant Prostate Cancer (CRPC) / Hormone Refractory Prostate Cancer1
4CompletedTreatmentProstate Cancer2
4RecruitingTreatmentMetastatic Hormone Refractory Prostate Cancer1
Not AvailableNot Yet RecruitingNot AvailableProstate Cancer, Castration Resistant1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Kit60 mg/1.5mL
SolutionIntravenous40 mg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5438072No1995-08-012014-05-22Us
US5698582No1997-12-162012-07-03Us
US6372780No2002-04-162016-03-26Us
US6387946No2002-05-142016-03-26Us
US8927592Yes2015-01-062031-04-27Us
US7241907Yes2007-07-102026-06-10Us
US5847170Yes1998-12-082021-09-26Us
US6331635No2001-12-182016-03-26Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00413 mg/mLALOGPS
logP3.69ALOGPS
logP4.2ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)11.97ChemAxon
pKa (Strongest Basic)-3.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area202.45 Å2ChemAxon
Rotatable Bond Count15ChemAxon
Refractivity213.4 m3·mol-1ChemAxon
Polarizability86.39 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9535
Blood Brain Barrier-0.9825
Caco-2 permeable-0.7945
P-glycoprotein substrateSubstrate0.8287
P-glycoprotein inhibitor IInhibitor0.6646
P-glycoprotein inhibitor IIInhibitor0.5887
Renal organic cation transporterNon-inhibitor0.933
CYP450 2C9 substrateNon-substrate0.8236
CYP450 2D6 substrateNon-substrate0.882
CYP450 3A4 substrateSubstrate0.7256
CYP450 1A2 substrateNon-inhibitor0.8197
CYP450 2C9 inhibitorNon-inhibitor0.8654
CYP450 2D6 inhibitorNon-inhibitor0.8935
CYP450 2C19 inhibitorNon-inhibitor0.8429
CYP450 3A4 inhibitorNon-inhibitor0.6339
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9068
Ames testNon AMES toxic0.8028
CarcinogenicityNon-carcinogens0.9264
BiodegradationNot ready biodegradable0.9926
Rat acute toxicity2.6378 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9907
hERG inhibition (predictor II)Non-inhibitor0.7906
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as taxanes and derivatives. These are diterpenoids with a structure based either on the taxane skeleton, or a derivative thereof. In term of phytochemistry, several derivatives of the taxane skeleton exist: 2(3->20)-abeotaxane, 3,11-cyclotaxane, 11(15->1),11(10->9)-abeotaxane, 3,8-seco-taxane, and 11(15->1)-abeotaxane, among others. More complex skeletons have been found recently, which include the taxane-derived [3.3.3] propellane ring system.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Diterpenoids
Direct Parent
Taxanes and derivatives
Alternative Parents
Benzoic acid esters / Tricarboxylic acids and derivatives / Benzoyl derivatives / Fatty acid esters / Monosaccharides / Tertiary alcohols / Carbamate esters / Secondary alcohols / Oxetanes / Carboxylic acid esters
show 8 more
Substituents
Taxane diterpenoid / Benzoate ester / Benzoic acid or derivatives / Tricarboxylic acid or derivatives / Benzoyl / Fatty acid ester / Monosaccharide / Monocyclic benzene moiety / Benzenoid / Fatty acyl
show 22 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
tetracyclic diterpenoid (CHEBI:63584)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Binder
General Function
Structural constituent of cytoskeleton
Specific Function
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
Gene Name
TUBA4A
Uniprot ID
P68366
Uniprot Name
Tubulin alpha-4A chain
Molecular Weight
49923.995 Da
References
  1. JEVTANA - cabazitaxel [Link]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Binder
General Function
Structural constituent of cytoskeleton
Specific Function
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain (By similarity).
Gene Name
TUBB1
Uniprot ID
Q9H4B7
Uniprot Name
Tubulin beta-1 chain
Molecular Weight
50326.56 Da
References
  1. JEVTANA - cabazitaxel [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. JEVTANA - cabazitaxel [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. JEVTANA - cabazitaxel [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. JEVTANA - cabazitaxel [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. JEVTANA - cabazitaxel [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. JEVTANA - cabazitaxel [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. JEVTANA - cabazitaxel [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da
References
  1. JEVTANA - cabazitaxel [Link]

Drug created on September 14, 2010 10:21 / Updated on December 16, 2018 06:53